MARKET

QURE

QURE

Uniqure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.00
-0.47
-1.25%
After Hours: 35.00 -2 -5.41% 19:46 02/25 EST
OPEN
37.18
PREV CLOSE
37.47
HIGH
37.43
LOW
35.77
VOLUME
449.27K
TURNOVER
--
52 WEEK HIGH
71.45
52 WEEK LOW
33.59
MARKET CAP
1.65B
P/E (TTM)
-9.8730
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
UniQure (QURE) to Report Q4 Results: Wall Street Expects Earnings Growth
Zacks.com · 3d ago
UniQure (QURE) to Report Q4 Results: Wall Street Expects Earnings Growth
Zacks.com · 3d ago
The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 19)
Benzinga · 6d ago
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)
Benzinga · 02/18 13:14
Stocks Making New 52-Week Highs/Lows For Wednesday, Feb. 17, 2021 (Via Benzinga Pro's Signals Tool)
52-Week Highs: Sanderson Farms (SAFM) SPDR Select Sector Fund - Financial ETF (XLF) Greenpro Capital (GRNQ) America's Car-Mart (CRMT) Angion Biomedica (ANGN) Shineco (TYHT) Sigmatron International
Benzinga · 02/17 19:47
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Simply Wall St. · 02/10 10:22
The Bullish Piece Of News That Caused This Gene Therapy Stock To Pop
Investor's Business Daily · 02/08 21:40
DJ UniQure's Stock Rallies 7% On Positive Safety Data For Huntington's Disease Treatment -- MarketWatch
Dow Jones · 02/08 19:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QURE. Analyze the recent business situations of Uniqure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QURE stock price target is 68.67 with a high estimate of 92.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 300
Institutional Holdings: 40.98M
% Owned: 92.10%
Shares Outstanding: 44.50M
TypeInstitutionsShares
Increased
57
5.76M
New
55
-2.14M
Decreased
52
3.21M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Non-Executive Chairman/Independent Director
philip Astley-Sparke
Non-Executive Chairman/Independent Director
Philip Astley-Sparke
President
Ricardo Dolmetsch
Chief Executive Officer/Chief Financial Officer/Executive Director
Matthew Kapusta
Executive Vice President
Alexander Kuta
Executive Director
Robert Gut
Director
Leonard Post
Non-Executive Independent Director
Madhavan Balachandran
Non-Executive Independent Director
Jack Kaye
Non-Executive Independent Director
David Meek
Non-Executive Independent Director
Paula Soteropoulos
Non-Executive Independent Director
Jeremy Springhorn
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers kinds of Uniqure NV stock information, including NASDAQ:QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.